Country-specific information for Ukrainian residents

• Name: -
• Phone: -
• Email: ucms.org@gmail.com
• Language: Ukrainian, English

• N/A

1. Address of a friend or somebody else
2. Medical insurance
3. Financial support for refugees
4. Find an apartments and work (disability status)

Duration of obtaining medical insurance

• 1-2 weeks

Where can people get specialised MS care?

• It is available, but no further information

What treatments for Multiple Sclerosis are available in Ukraine?

• Interferons
• Fingolimod
• Mitocantrone
• Dymetyl fumarate

Do pharmaceutical companies allow/support patients to continue a clinical study which they started in Ukraine?

• Clinical trials in Ukraine might have been changed and replaced to another country.
• You can find below the information provided by specific pharmaceutical companies.
• For more information consult with your doctors or representatives of the pharma company and via Internet.

Sanofi:

• Sanofi is fully mobilized and launched a task force focused on protecting the continuity of the treatment for all the patients enrolled in their clinical trials, including for those who have made the difficult choice to leave their country.  They are working tirelessly to identify routes to secure resupply of the study drugs and maintain oversight of the patients’ care.
• Sanofi’s Foundation S has donated, so far, 30 million daily treatments of essential medicines and vaccines, potentially helping 20.5 million people. From those, about 33,000 daily doses of MS treatments has been donated for 1,200 MS Ukrainian patients.
• Because of the unique nature of the industry, and in line with international law, Sanofi remains committed to continuing to supply life-saving or essential medicines and vaccines to the people of Russia who need them. Likewise, they are mobilized to ensure treatment continuity for ongoing Russian patients participating to clinical trials. 
• If you are contacted by an individual who was participating in a Sanofi clinical trial in Ukraine and is now seeking continued participation through a site in your country, please contact the local Sanofi clinical trial team through Medinfo.Ukraine@sanofi.com.  A member of their team will then be able to help you communicate options.
• For more information on Sanofi’s response to the situation in Ukraine please go to their website: https://www.sanofi.com/en/media-room/our-response-to-the-situation-in-ukraine
• Other actions taken by Sanofi in Ukraine:
  • Aubagio product has been donated to 3 hospitals in different cities of Ukraine (donation in progress):
    • Center 1: Kyiv City Center for Multiple Sclerosis at Kyiv City Clinical Hospital
    • Center 2: Dnipropetrovsk Regional Clinical Hospital, Neurological Department
    • Center 3: Lviv National Medical University

• Email address for patients: patientcare@roche.com
• Read more through this media release about Roche’s donation of essential medicines.
• Roche understands the concern felt by patients and they are doing everything they can to provide ongoing access to Roche medicines and diagnostics both in and outside Ukraine. They have sufficient products in Ukraine but are hindered by the severe destruction of local infrastructure, and disruption to logistics and supply chain channels. They are doing all they can to ensure products reach centers that remain able to provide care and are seeking alternative means of distribution for individual patients where this is not the case.
• With regards to displaced persons or refugees, a number of neighbouring countries have confirmed they will be eligible for the same access to healthcare as local citizens. Roche is working with healthcare providers in these countries to ensure sufficient supply is available. Additionally, Roche is in contact with specialist centres to identify sites that have capacity to take on the care of patients who have been participating in clinical studies.
• Roche established a global toll-free hotline number and invite clinical trial participants, patients that are receiving a Roche drug, clinical trial investigators or coordinators, and healthcare providers to call. The team will do its best to provide everyone who is in need with the appropriate information and support. The hotline is available in multilingual and can be reached on the following number:  +36 146 182 58

• Merck’s global team has been in contact with their colleagues managing Ukraine in order to track the situation of the few patients they have there and ensure they are able to still get access to medicines marketed by Merck.
• Contact information for Ukrainian patients participating in one of Merck’s Phase-III clinical trials of evobrutinib (EVOLUTION RMS) :
• Ukrainian number:  +38 0800 50 28 66 (Ukrainian native speaker)
• German number: +49 800 100 71 05 (English speaking helpdesk)
• Website: https://ua.evolutionstudies.com/  (Ukrainian version)
• Website: https://ru-ua.evolutionstudies.com/#!/  (Russian version)

• Biogen does not have any registrations for MS products in Ukraine
• The Biogen Foundation has provided a $250,000 grant as well as launched an employee giving campaign that doubles employees’ contributions to provide medical supplies, food, water, shelter, and other essential support. Contributions to date have surpassed more than $1 million in grants, in-kind materials, volunteering, and other support.